Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors

  • Technology appraisal guidance
  • TA813
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators